Innate immune pathways and antigen-presenting cells

Innate immune pathways and antigen-presenting cells (APCs) constitute the foundational components of the immune system's ability to detect and respond to threats. Innate pathways rely on pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs) and the cGAS-STING pathway, to identify pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) [Janeway et al., 2002, Nature]. APCs, primarily dendritic cells and macrophages, bridge the innate and adaptive systems by processing these signals and presenting antigens via MHC molecules to T-cells [Banchereau et al., 1998, Nature]. In the context of oncology, therapeutic strategies often focus on activating these pathways to reverse the immunosuppressive tumor microenvironment and promote "in situ" vaccination [Corrales et al., 2015, Cell Reports]. Drugs such as TLR agonists and STING activators are designed to enhance APC maturation and the subsequent priming of tumor-specific CD8+ T-cells [Mellman et al., 2011, Nature]. However, as a target designation, this term is overly broad, representing a complex network of signaling cascades and cell types rather than a single druggable protein. Effective clinical application requires precise targeting of specific nodes within these pathways to balance potent anti-tumor activity against the risk of systemic inflammatory toxicities [Coffman et al., 2010, Immunity].

Other names

Innate immunityAntigen presentation systemPRR signaling pathwaysInnate immune system

Activation of pattern recognition receptors (PRRs) and enhancement of MHC-mediated antigen presentation to T-cells.